Chapter 11: Attention Deficit Hyperactivity Disorder and Its Treatment

Attention Deficit Hyperactivity Disorder represents a neurobiological condition fundamentally rooted in dysregulation of neurotransmitter systems within prefrontal cortical circuits. The disorder manifests through three primary symptom domains—inattention, hyperactivity, and impulsivity—each corresponding to specific anatomical regions and functional deficits. Dorsolateral prefrontal cortex dysfunction underlies executive impairments including working memory deficits and problem-solving difficulties, while the dorsal anterior cingulate cortex involvement relates to challenges in selective attention and sustained focus. The orbital frontal cortex contributes to impulse control dysfunction, and prefrontal motor regions mediate hyperkinetic symptoms. The neurochemical foundation of ADHD involves suboptimal dopamine and norepinephrine signaling that fails to properly modulate cortical signal transmission. Optimal prefrontal function requires a moderate stimulation state where norepinephrine acts via alpha 2A receptors to strengthen neural signals through closure of hyperpolarization-activated cyclic nucleotide-gated channels, while dopamine operating through D1 receptors reduces baseline neural noise, collectively establishing an ideal signal-to-noise ratio within pyramidal neurons. Pharmacological interventions restore these neurotransmitter systems to functional ranges through distinct mechanisms. Stimulant medications including methylphenidate and amphetamine increase dopamine and norepinephrine availability by blocking their respective reuptake transporters, though their mechanisms differ—methylphenidate acts allosterically while amphetamine functions as a competitive inhibitor. The abuse liability of stimulants correlates directly with pharmacokinetic profiles; rapid delivery producing high dopamine transporter occupancy generates phasic dopamine surges associated with euphoria and addiction vulnerability, whereas sustained-release formulations maintain therapeutic dopamine transporter occupancy near fifty to sixty percent, enhancing tonic signaling without reward pathway activation. Non-stimulant alternatives offer valuable options particularly for patients with comorbid conditions. Selective norepinephrine reuptake inhibitors like atomoxetine selectively elevate norepinephrine and dopamine within prefrontal regions while sparing reward-related areas, reducing abuse potential and anxiety exacerbation. Alpha 2A adrenergic agonists such as controlled-release guanfacine provide augmentation through direct receptor activation and demonstrate particular utility for aggressive or oppositional behavioral components potentially mediated by ventromedial prefrontal dysfunction.